home / stock / wuxay / wuxay quote
Last: | $3.76 |
---|---|
Change Percent: | -2.91% |
Open: | $3.6843 |
Close: | $3.76 |
High: | $3.76 |
Low: | $3.6843 |
Volume: | 1,170 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.76 | $3.6843 | $3.76 | $3.76 | $3.6843 | 1,170 | 07-03-2024 |
$3.58 | $3.79 | $3.58 | $3.79 | $3.58 | 9,374 | 07-02-2024 |
$3.6036 | $3.62 | $3.6036 | $3.71 | $3.6036 | 3,483 | 07-01-2024 |
$3.705 | $3.705 | $3.705 | $3.73 | $3.705 | 1,112 | 06-28-2024 |
$3.8 | $3.83 | $3.8 | $3.83 | $3.8 | 972 | 06-27-2024 |
$3.81 | $3.97 | $3.81 | $3.97 | $3.81 | 5,522 | 06-26-2024 |
$3.8 | $3.8 | $3.8 | $3.885 | $3.73 | 2,976 | 06-25-2024 |
$3.86 | $3.865 | $3.86 | $3.865 | $3.86 | 1,903 | 06-24-2024 |
$3.885 | $3.8686 | $3.885 | $3.885 | $3.86 | 1,897 | 06-21-2024 |
$3.92 | $3.93 | $3.92 | $3.93 | $3.89 | 8,246 | 06-20-2024 |
$3.99 | $4.04 | $3.99 | $4.04 | $3.87 | 10,547 | 06-19-2024 |
$3.99 | $4.04 | $3.99 | $4.04 | $3.87 | 10,547 | 06-18-2024 |
$4.19 | $4.17 | $4.19 | $4.2 | $4.144 | 5,777 | 06-17-2024 |
$4.41 | $4.34 | $4.41 | $4.51 | $4.17 | 2,004 | 06-14-2024 |
$4.42 | $4.62 | $4.42 | $4.62 | $4.42 | 641 | 06-13-2024 |
$4.625 | $4.69 | $4.625 | $4.69 | $4.58 | 6,287 | 06-12-2024 |
$4.29 | $4.302 | $4.29 | $4.302 | $4.17 | 1,806 | 06-11-2024 |
$4.29 | $4.3 | $4.29 | $4.3 | $4.29 | 1,227 | 06-10-2024 |
$4.3 | $4.274 | $4.3 | $4.3 | $4.274 | 2,590 | 06-07-2024 |
$4.37 | $4.4 | $4.37 | $4.43 | $4.35 | 1,083 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Wuxi AppTec Co. Ltd. ADR Company Name:
WUXAY Stock Symbol:
OTCMKTS Market:
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations PR Newswire Revenue Reached RMB7,982 Million ; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time PR Newswire Revenue Up 2.5% Year-over-Year to RMB40,341 Million ; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributa...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. ...